MDM2 and sarcoma: The mutational status of 94T778 is unknown, but it would be of interest to determine whether TP53 is mutated in this LPS line, which is more sensitive than the other line of this type of sarcoma (93T449) to eribulin, or to determine whether the expression/amplification levels of MDM2, a negative regulator of p53, are higher in 94T778.